Lutathera in Somatostatin Neuroendocrine Tumors

Lutathera in Somatostatin Neuroendocrine Tumors

Contact

 If you are interested in participating in the study or want to learn more, please get in touch. Contact us
This study is no longer recruiting.

Description

This study involves taking a study drug called Lutathera. The overall goal of this study is to see if Lutathera is safe in adolescent subjects with either a gastroenteropancreatic neuroendocrine tumor (GEP-NET), or a pheochromocytoma and/or paraganglioma (PPGL). This study will also look at the levels of radioactivity after Lutathera administration.

Eligibility and criteria
IRB Number:
21-018820
Eligible age range:
12 years - 17 years
Clinical trial phase:
Phase II
Official title:
A Multicenter Open-Label Study to Evaluate Safety and Dosimetry of Lutathera in Adolescent Patients with Somatostatin Receptor Positive Gastroenteropancreatic Neuroendocrine (GEP-NET) Tumors, Pheochromocytoma and Paragangliomas

Related specialties
Smiling CHOP patient holding shopping bag

We need families like you

Your time and participation make a difference in supporting the work of the Research Institute and children in our community. Learn more about opportunities to participate in our research.